PD-1/PD-L1-IN-NP19|T36900|TargetMol | United States | Manufacturer

Price	$376	$1140	$1490
Package	5mg	25mg	50mg

Product Details

Product Name: PD-1/PD-L1-IN-NP19	CAS No.: 2377916-66-8
Supply Ability: 10g	Release date: 2025/10/27

Product Introduction

Bioactivity

Name	PD-1/PD-L1-IN-NP19
Description	PD-1/PD-L1-IN-NP19, a PD-1/PD-L1 inhibitor, exhibits an IC50 of 12.5 nM against the human PD-1/PD-L1 interaction, potentially activating the tumor immune microenvironment and contributing to its antitumor effects[1].
In vitro	PD-1/PD-L1-IN-NP19 (compound NP19) (0.37-10 μM; 72 h) significantly elevates IFN-γ production in a dose-dependent manner from T cells co-cultured with tumor cells[1]. PD-1/PD-L1-IN-NP19 exhibits much lower activity for inhibiting mouse PD-1/PD-L1 interaction (IC50 >1 μM) compared to human PD-1/PD-L1 interaction (IC50=12.5 nM)[1]. PD-1/PD-L1-IN-NP19 (10 μM; 48 h) shows no apparent cytotoxic effects on A549, MCF-7, and B16-F10 cells at a concentration of 10 μM[1].
In vivo	PD-1/PD-L1-IN-NP19 (compound NP19) (25-100 mg/kg; intragastric gavage once daily for 15 days) significantly inhibits melanoma tumor growth in mice. Additionally, PD-1/PD-L1-IN-NP19 (25 mg/kg; i.p. daily for 14 days) exhibits substantial antitumor efficacy with a tumor growth inhibition (TGI) of 76.5% and is well-tolerated in an H22 hepatoma mouse model. In rats, PD-1/PD-L1-IN-NP19 (1 mg/kg; i.v.) has a half-life (t1/2) of 1.5±0.5 hours, clearance rate (CL) of 0.9±0.2 L/h/kg, and an apparent distribution volume (Vss) of 2.1±0.5 L/kg. Furthermore, when administered orally at 10 mg/kg, PD-1/PD-L1-IN-NP19 shows an absorption time (Tmax) of 0.6±0.2 hours, a long half-life (t1/2) of 10.9±7.7 hours, and an oral bioavailability (F) of 5% in rats.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 1.8 mg/mL (3.2 mM), Sonication is recommended.
Keywords	PD-L1 \| PDL1 \| PD-1/PD-L-1-IN-NP19 \| PD1/PDL1INNP19 \| PD-1/PD-L1 \| PD1/PDL1 \| PD-1 \| PD1 \| PD 1/PD L1 IN NP19
Inhibitors Related	LSD1-IN-24 \| PD-1/PD-L1-IN-9 \| Sulfamethoxypyridazine \| BMS-202 \| PD-1-IN-22 \| BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride \| IMMH 010 maleate \| Camrelizumab \| LSD1-IN-27 \| BMS-1 \| Anti-Mouse PD-1 Antibody (RMP1-14) \| PD-L1-IN-3

Company Profile Introduction

TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds. 170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.

Recommended supplier

Product name	Price		Suppliers	Update time
PD-1/PD-L1-IN-9	$55.00/1mg	VIP6Y	TargetMol Chemicals Inc.	2025-11-09
PD-L1 Protein, Human, Recombinant	$451.00/100μg	VIP4Y	TargetMol Chemicals Inc.	2025-11-04
PD-1/PD-L1 Inhibitor 3 USP/EP/BP	$1.10/1g	VIP5Y	Dideu Industries Group Limited	2021-08-17

Min. Order:
Supply Ability:	10g
Update Time:	2025-10-27

PD-1/PD-L1-IN-NP19 NEW

Product Details

Product Introduction

Bioactivity

Company Profile Introduction

You may like

Recommended supplier

TargetMol Chemicals Inc.